This event has ended.
It is a pivotal moment for psychedelics in terms of both their potential to treat a host of mental health conditions, as well as to elevate creativity and human potential. Today, more than 50 publicly traded psychedelic companies are listed on US exchanges alone, and it has been estimated that the market for psychedelics could exceed $10 billion by 2027. Public perception of psychedelics is fast approaching a tipping point, aided in no small part by the bestselling book How To Change Your Mind, written by the highly respected author Michael Pollan, which was recently adapted for a Netflix docuseries, as well as enthusiastic endorsements from public figures, going back to Steve Jobs, and now ranging from Elon Musk to Gwyneth Paltrow and Green Bay Packers legend Aaron Rodgers. More importantly, there is a rapidly growing volume of compelling research from respected bodies backing the efficacy of these drugs, and the FDA has granted breakthrough therapy status to psilocybin and MDMA.At such a critical juncture, CORE: is thrilled to welcome three individuals who have been at the tip of the spear of psychedelic treatments, and together they will share their unrivaled insights into the vast opportunities, unique challenges, and significant responsibilities that come with working in such a singular, sensitive space. They include Neil Markey, a former elite US Army ranger who later joined corporate life at McKinsey, who is now the co-founder and CEO of Beckley Retreats, which runs psilocybin experiences in Jamaica and the Netherlands. Dr. Gita Vaid, a psychiatrist, psychoanalyst, and foremost specialist in ketamine treatment, who is also co-founder of the Center for Natural Intelligence, which is dedicated to psychedelic psychotherapy innovation and clinical practice. And Dr. Ben Sessa, who featured prominently in the Michael Pollan docuseries thanks to his hugely significant work with psychedelics, specifically MDMA, who is also the co-founder and Head of Psychedelic Medicine at Awakn.